Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions

A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of structure–activity relationships (SAR) in conjunctio...

Full description

Saved in:
Bibliographic Details
Published inACS medicinal chemistry letters Vol. 4; no. 1; pp. 37 - 40
Main Authors Tuttle, Jamison B, Anderson, Marie, Bechle, Bruce M, Campbell, Brian M, Chang, Cheng, Dounay, Amy B, Evrard, Edelweiss, Fonseca, Kari R, Gan, Xinmin, Ghosh, Somraj, Horner, Weldon, James, Larry C, Kim, Ji-Young, McAllister, Laura A, Pandit, Jayvardhan, Parikh, Vinod D, Rago, Brian J, Salafia, Michelle A, Strick, Christine A, Zawadzke, Laura E, Verhoest, Patrick R
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 10.01.2013
Subjects
Letter
dose response modeling
irreversible inhibition
kynurenine amino transferase
hydroxamic acid
schizophrenia
kynurenic acid
in vivo microdialysis
aryl hydrocarbon receptor
Online AccessGet full text

Cover

Abstract A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of structure–activity relationships (SAR) in conjunction with X-ray crystallography led to the discovery of hydroxamate 4, a disubstituted analogue that has a significant potency enhancement due to a novel interaction with KAT II. The use of k inact/K i to assess potency was critical for understanding the SAR in this series and for identifying compounds with improved pharmacodynamic profiles.
AbstractList A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of structure–activity relationships (SAR) in conjunction with X-ray crystallography led to the discovery of hydroxamate 4, a disubstituted analogue that has a significant potency enhancement due to a novel interaction with KAT II. The use of k inact/K i to assess potency was critical for understanding the SAR in this series and for identifying compounds with improved pharmacodynamic profiles.
A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of structure–activity relationships (SAR) in conjunction with X-ray crystallography led to the discovery of hydroxamate 4 , a disubstituted analogue that has a significant potency enhancement due to a novel interaction with KAT II. The use of k inact / K i to assess potency was critical for understanding the SAR in this series and for identifying compounds with improved pharmacodynamic profiles.
A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of structure-activity relationships (SAR) in conjunction with X-ray crystallography led to the discovery of hydroxamate 4, a disubstituted analogue that has a significant potency enhancement due to a novel interaction with KAT II. The use of k inact/K i to assess potency was critical for understanding the SAR in this series and for identifying compounds with improved pharmacodynamic profiles.A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of structure-activity relationships (SAR) in conjunction with X-ray crystallography led to the discovery of hydroxamate 4, a disubstituted analogue that has a significant potency enhancement due to a novel interaction with KAT II. The use of k inact/K i to assess potency was critical for understanding the SAR in this series and for identifying compounds with improved pharmacodynamic profiles.
Author Rago, Brian J
Pandit, Jayvardhan
Ghosh, Somraj
McAllister, Laura A
Zawadzke, Laura E
Dounay, Amy B
Strick, Christine A
Evrard, Edelweiss
James, Larry C
Salafia, Michelle A
Tuttle, Jamison B
Bechle, Bruce M
Gan, Xinmin
Parikh, Vinod D
Verhoest, Patrick R
Chang, Cheng
Anderson, Marie
Kim, Ji-Young
Campbell, Brian M
Fonseca, Kari R
Horner, Weldon
AuthorAffiliation Pfizer Worldwide Research and Development
AuthorAffiliation_xml – name: Pfizer Worldwide Research and Development
Author_xml – sequence: 1
  givenname: Jamison B
  surname: Tuttle
  fullname: Tuttle, Jamison B
  email: jamison.b.tuttle@pfizer.com
– sequence: 2
  givenname: Marie
  surname: Anderson
  fullname: Anderson, Marie
– sequence: 3
  givenname: Bruce M
  surname: Bechle
  fullname: Bechle, Bruce M
– sequence: 4
  givenname: Brian M
  surname: Campbell
  fullname: Campbell, Brian M
– sequence: 5
  givenname: Cheng
  surname: Chang
  fullname: Chang, Cheng
– sequence: 6
  givenname: Amy B
  surname: Dounay
  fullname: Dounay, Amy B
– sequence: 7
  givenname: Edelweiss
  surname: Evrard
  fullname: Evrard, Edelweiss
– sequence: 8
  givenname: Kari R
  surname: Fonseca
  fullname: Fonseca, Kari R
– sequence: 9
  givenname: Xinmin
  surname: Gan
  fullname: Gan, Xinmin
– sequence: 10
  givenname: Somraj
  surname: Ghosh
  fullname: Ghosh, Somraj
– sequence: 11
  givenname: Weldon
  surname: Horner
  fullname: Horner, Weldon
– sequence: 12
  givenname: Larry C
  surname: James
  fullname: James, Larry C
– sequence: 13
  givenname: Ji-Young
  surname: Kim
  fullname: Kim, Ji-Young
– sequence: 14
  givenname: Laura A
  surname: McAllister
  fullname: McAllister, Laura A
– sequence: 15
  givenname: Jayvardhan
  surname: Pandit
  fullname: Pandit, Jayvardhan
– sequence: 16
  givenname: Vinod D
  surname: Parikh
  fullname: Parikh, Vinod D
– sequence: 17
  givenname: Brian J
  surname: Rago
  fullname: Rago, Brian J
– sequence: 18
  givenname: Michelle A
  surname: Salafia
  fullname: Salafia, Michelle A
– sequence: 19
  givenname: Christine A
  surname: Strick
  fullname: Strick, Christine A
– sequence: 20
  givenname: Laura E
  surname: Zawadzke
  fullname: Zawadzke, Laura E
– sequence: 21
  givenname: Patrick R
  surname: Verhoest
  fullname: Verhoest, Patrick R
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24900560$$D View this record in MEDLINE/PubMed
BookMark eNptkUlPHDEQhS1ExBYO-QORL5Hg0MFLrzkgsSW0ghIk4GxVm-oZo24bbPdE8-_j0QAiEaeyVN97T361Szats0jIJ86-cib40ThIxoSsFhtkhzd5nRV1VWy-eW-T3RAeGCubqmJbZFvkDWNFyXaIu4l-0nHymJ1CwHt6jsHMLHU9bb3HBfpgugHp5TSCpT9Pbmnb0tbOTWei8-EbPTdBu4QtV5Jf-Ideu4hWL7MLOwerjZ0lPKIHHY2z4SP50MMQcP957pG77xe3Z5fZ1e8f7dnJVQayYjGTdV43WmhALpuSlVxjU-lGANaSV0VfQ18Ah1oKyXuhe-wE0wC56EXRca3lHjle-z5O3Yj3Gm30MKhHb0bwS-XAqH831szVzC1UzkTFZZEMDp4NvHuaMEQ1pp_iMIBFNwXFC5mzpkwlJvTz26zXkJeWE3C0BrR3IXjslTYRVn2kaDMoztTqjur1jklx-J_ixfQ99suaBR3Ug5u8TcW-w_0FpL6rHQ
CitedBy_id crossref_primary_10_3390_ijms25169082
crossref_primary_10_1021_acsomega_8b02287
crossref_primary_10_1021_ja512690x
crossref_primary_10_1021_bi4015677
crossref_primary_10_1021_jacs_7b00962
crossref_primary_10_1038_srep18880
crossref_primary_10_1002_pro_3119
crossref_primary_10_1007_s00044_017_1950_6
crossref_primary_10_3390_ijms17060946
crossref_primary_10_3390_ph14121291
crossref_primary_10_1124_dmd_114_059204
crossref_primary_10_1016_j_ab_2016_02_003
crossref_primary_10_1016_j_pep_2016_01_004
crossref_primary_10_1007_s44371_024_00037_3
crossref_primary_10_3390_ijms17040446
crossref_primary_10_1016_j_neuropharm_2017_04_023
crossref_primary_10_1016_j_tetlet_2017_01_008
crossref_primary_10_3389_fmolb_2019_00007
crossref_primary_10_1016_j_bmcl_2013_02_039
crossref_primary_10_1016_j_ejmech_2023_115258
crossref_primary_10_1124_mol_118_111625
Cites_doi 10.1016/0306-4522(93)90464-Q
10.1016/S0304-3940(01)02242-X
10.1073/pnas.96.17.9459
10.1503/jpn.090180
10.1073/pnas.0806121105
10.2165/00023210-200923020-00001
10.1016/j.schres.2005.07.013
10.1016/S0022-3565(24)37160-5
10.1002/cmdc.200500095
10.1523/JNEUROSCI.21-19-07463.2001
10.1038/npp.2010.39
10.1007/s00702-011-0763-x
10.1002/prot.20417
10.1146/annurev.biochem.73.011303.074021
10.1021/ml200204m
10.1007/s00018-009-0166-4
10.1016/S0006-3223(01)01078-2
ContentType Journal Article
Copyright Copyright © 2012 American Chemical Society
Copyright © 2012 American Chemical Society 2012 American Chemical Society
Copyright_xml – notice: Copyright © 2012 American Chemical Society
– notice: Copyright © 2012 American Chemical Society 2012 American Chemical Society
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.1021/ml300237v
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1948-5875
EndPage 40
ExternalDocumentID PMC4027135
24900560
10_1021_ml300237v
a481165600
Genre Journal Article
GroupedDBID -
4.4
53G
55A
7~N
AABXI
ABMVS
ABUCX
ACGFS
ACS
ADACO
ADBBV
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAWUL
DIK
EBS
ED
ED~
EJD
F5P
GNL
GX1
HYE
IH9
JG
JG~
OK1
P2P
RNS
ROL
RPM
UI2
VF5
VG9
W1F
XKZ
---
5VS
AAYXX
ABBLG
ABJNI
ABLBI
ABQRX
ACGFO
ADHLV
AHGAQ
AOIJS
BAANH
CITATION
CUPRZ
GGK
NPM
7X8
5PM
ID FETCH-LOGICAL-a370t-38489c2cae1396061ce97c92ae83175f8af5a1a83231f2cfeb20caa42f25b1cc3
IEDL.DBID ACS
ISSN 1948-5875
IngestDate Thu Aug 21 17:50:47 EDT 2025
Fri Jul 11 11:59:19 EDT 2025
Mon Jul 21 06:01:21 EDT 2025
Thu Apr 24 23:07:34 EDT 2025
Tue Jul 01 05:13:18 EDT 2025
Thu Aug 27 13:42:37 EDT 2020
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords dose response modeling
irreversible inhibition
kynurenine amino transferase
hydroxamic acid
schizophrenia
kynurenic acid
in vivo microdialysis
aryl hydrocarbon receptor
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a370t-38489c2cae1396061ce97c92ae83175f8af5a1a83231f2cfeb20caa42f25b1cc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 24900560
PQID 1534096560
PQPubID 23479
PageCount 4
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4027135
proquest_miscellaneous_1534096560
pubmed_primary_24900560
crossref_citationtrail_10_1021_ml300237v
crossref_primary_10_1021_ml300237v
acs_journals_10_1021_ml300237v
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
XKZ
7~N
VG9
W1F
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
AQSVZ
ED~
UI2
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-01-10
PublicationDateYYYYMMDD 2013-01-10
PublicationDate_xml – month: 01
  year: 2013
  text: 2013-01-10
  day: 10
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle ACS medicinal chemistry letters
PublicationTitleAlternate ACS Med. Chem. Lett
PublicationYear 2013
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References Erhardt S. (ref6/cit6) 2001; 313
Moroni F. (ref3/cit3) 2012; 119
Mileni M. (ref18/cit18) 2008; 105
Eliot A. C. (ref2/cit2) 2004; 73
Dounay A. B. (ref13/cit13) 2012; 3
ref19/cit19
Gallivan J. P. (ref25/cit25) 1999; 96
ref16/cit16
Erhardt S. (ref10/cit10) 2009; 23
Parsons C. G. (ref5/cit5) 1998; 283
Pellicciari R. (ref15/cit15) 2006; 1
Nilsson L. K. (ref7/cit7) 2005; 80
ref14/cit14
Schwarcz R. (ref8/cit8) 2001; 50
Olsson S. K. (ref9/cit9) 2010; 35
Hilmas C. (ref4/cit4) 2001; 21
Schmidt W. (ref12/cit12) 1993; 55
Crowley P. B. (ref26/cit26) 2005; 59
Han Q. (ref1/cit1) 2010; 67
Potter M. C. (ref11/cit11) 2010; 35
15726638 - Proteins. 2005 May 1;59(2):231-9
22215208 - J Neural Transm (Vienna). 2012 Feb;119(2):133-9
20336058 - Neuropsychopharmacology. 2010 Jul;35(8):1734-42
19826765 - Cell Mol Life Sci. 2010 Feb;67(3):353-68
24900455 - ACS Med Chem Lett. 2012 Jan 25;3(3):187-92
16892388 - ChemMedChem. 2006 May;1(5):528-31
19173370 - CNS Drugs. 2009;23(2):91-101
11567036 - J Neurosci. 2001 Oct 1;21(19):7463-73
8350986 - Neuroscience. 1993 Jul;55(1):177-84
18753625 - Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12820-4
16125901 - Schizophr Res. 2005 Dec 15;80(2-3):315-22
10449714 - Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9459-64
16350889 - Methods Biochem Anal. 2005;46:1-265
11684348 - Neurosci Lett. 2001 Nov 2;313(1-2):96-8
11600105 - Biol Psychiatry. 2001 Oct 1;50(7):521-30
20420770 - J Psychiatry Neurosci. 2010 May;35(3):195-9
9400002 - J Pharmacol Exp Ther. 1997 Dec;283(3):1264-75
15189147 - Annu Rev Biochem. 2004;73:383-415
References_xml – volume: 55
  start-page: 177
  year: 1993
  ident: ref12/cit12
  publication-title: Neuroscience
  doi: 10.1016/0306-4522(93)90464-Q
– volume: 313
  start-page: 96
  year: 2001
  ident: ref6/cit6
  publication-title: Neurosci. Lett.
  doi: 10.1016/S0304-3940(01)02242-X
– volume: 96
  start-page: 9459
  year: 1999
  ident: ref25/cit25
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.96.17.9459
– volume: 35
  start-page: 195
  year: 2010
  ident: ref9/cit9
  publication-title: J. Psychiatry Neurosci.
  doi: 10.1503/jpn.090180
– ident: ref14/cit14
– volume: 105
  start-page: 12820
  year: 2008
  ident: ref18/cit18
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.0806121105
– volume: 23
  start-page: 91
  year: 2009
  ident: ref10/cit10
  publication-title: CNS Drugs
  doi: 10.2165/00023210-200923020-00001
– volume: 80
  start-page: 315
  year: 2005
  ident: ref7/cit7
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2005.07.013
– volume: 283
  start-page: 1264
  year: 1998
  ident: ref5/cit5
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1016/S0022-3565(24)37160-5
– volume: 1
  start-page: 528
  year: 2006
  ident: ref15/cit15
  publication-title: ChemMedChem
  doi: 10.1002/cmdc.200500095
– volume: 21
  start-page: 7463
  year: 2001
  ident: ref4/cit4
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.21-19-07463.2001
– ident: ref16/cit16
– volume: 35
  start-page: 1734
  year: 2010
  ident: ref11/cit11
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2010.39
– ident: ref19/cit19
– volume: 119
  start-page: 133
  year: 2012
  ident: ref3/cit3
  publication-title: J. Neural Transm.
  doi: 10.1007/s00702-011-0763-x
– volume: 59
  start-page: 231
  year: 2005
  ident: ref26/cit26
  publication-title: Proteins: Struct., Funct., Bioinf.
  doi: 10.1002/prot.20417
– volume: 73
  start-page: 383
  year: 2004
  ident: ref2/cit2
  publication-title: Annu. Rev. Biochem.
  doi: 10.1146/annurev.biochem.73.011303.074021
– volume: 3
  start-page: 187
  year: 2012
  ident: ref13/cit13
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/ml200204m
– volume: 67
  start-page: 353
  year: 2010
  ident: ref1/cit1
  publication-title: J. Cell. Mol. Life Sci.
  doi: 10.1007/s00018-009-0166-4
– volume: 50
  start-page: 521
  year: 2001
  ident: ref8/cit8
  publication-title: Biol. Psychiatry
  doi: 10.1016/S0006-3223(01)01078-2
– reference: 20336058 - Neuropsychopharmacology. 2010 Jul;35(8):1734-42
– reference: 24900455 - ACS Med Chem Lett. 2012 Jan 25;3(3):187-92
– reference: 19826765 - Cell Mol Life Sci. 2010 Feb;67(3):353-68
– reference: 16125901 - Schizophr Res. 2005 Dec 15;80(2-3):315-22
– reference: 22215208 - J Neural Transm (Vienna). 2012 Feb;119(2):133-9
– reference: 16350889 - Methods Biochem Anal. 2005;46:1-265
– reference: 15189147 - Annu Rev Biochem. 2004;73:383-415
– reference: 15726638 - Proteins. 2005 May 1;59(2):231-9
– reference: 9400002 - J Pharmacol Exp Ther. 1997 Dec;283(3):1264-75
– reference: 11567036 - J Neurosci. 2001 Oct 1;21(19):7463-73
– reference: 16892388 - ChemMedChem. 2006 May;1(5):528-31
– reference: 8350986 - Neuroscience. 1993 Jul;55(1):177-84
– reference: 18753625 - Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12820-4
– reference: 11684348 - Neurosci Lett. 2001 Nov 2;313(1-2):96-8
– reference: 19173370 - CNS Drugs. 2009;23(2):91-101
– reference: 11600105 - Biol Psychiatry. 2001 Oct 1;50(7):521-30
– reference: 20420770 - J Psychiatry Neurosci. 2010 May;35(3):195-9
– reference: 10449714 - Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9459-64
SSID ssj0069770
Score 2.062229
Snippet A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a...
A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a...
SourceID pubmedcentral
proquest
pubmed
crossref
acs
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 37
SubjectTerms Letter
Title Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions
URI http://dx.doi.org/10.1021/ml300237v
https://www.ncbi.nlm.nih.gov/pubmed/24900560
https://www.proquest.com/docview/1534096560
https://pubmed.ncbi.nlm.nih.gov/PMC4027135
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LT9tAEB5Reuml70eAou1DqAcWvLt-pbeUQEmrVpEIUm7Wer1uogYbxUml8Os7s44DKbS9-LKztuydp2fmG4D3aCJ1ECvBrbAZR3vr8Ri9XJ4LsrfKS7OAeoe_fQ9Pz_0vw2C4Ae_-ksGX4vBiosiwRL_uwX0ZxhFFWJ2js0bdhujAuK7Htk8tRFHQwAfd3Eqmx1TrpueWP_lnWeQNO3PyCLpNt05dXvLzYD5LD8zVbfDGf73CY3i49DNZp2aMJ7Bhi6ew16-Bqhf7bHDdd1Xtsz3Wv4awXjyD8szBys6nln9CM5exriv0YGXOelMCfZqiJE0scykA9rUzYL0e6xWjcTqm6T0fWXdcGSoOXdAWVKSsX5JzvuDHxYgQPoofzP2LrNsqqudwfnI8ODrly9EMXKvIm3EV-3HbSKMtepAYAwlj25FpS21jckjyWOeBFhrVhRK5NDnG757R2pe5DFJhjHoBm0VZ2FfAbIZKJ5U28rPANyLTKTKM8qUXesrmUdqCXTy7ZClaVeKy5lIkq4_agg_NsSZmCWxO8zUmd5G-XZFe1mgedxG9aXgjQVmjBIoubDnHRwfKJ7Sc0GvBy5pXVrfBMJZgVXElWuOiFQHheK-vFOORw_PGEJ4GJW7970W34YF0wzioCHEHNpET7Gt0iWbprhMJvH4eit83VAgE
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwzV1bb9MwFLbGeIAX7pdyGQbBxMMyYjtpUiQeyrqpodtUaZ20t8xxnLVaSVDTgsJP4a_w5zjHuXQdk3iaxLMdx7GPz3dOfM53CHkLECldXzBLMx1bgLe25YOVayUM8VbYUexi7vDBYbt_7Hw5cU_WyK86FwYmkcNIubnEX7ILsA9fpwLxxfteBVAOdPED3LP8U9CDvXzH-d7uaKdvVRUELCk8e24J3_E7iiupwdABU50p3fFUh0vtI24mvkxcySRItWAJVwm4mbaS0uEJdyOmlIBxb5CbYPRwdOy6O0e1lm-D3WSSLTsOZi55bs1adHGqiHgqX0W8v8zYy9GYF-Bt7y753SyMiWo5317Mo2318xJn5P-5cvfIncqqpt3yGNwnazp9QDaHJS13sUVHyyyzfItu0uGSsLt4SLIjQ6K7mGnrM4B6THsmrIVmCQ1mSHE1A70x1dRceNBBd0SDgAbpeBJNsFbRR9qb5ApDYQt8BGCDDjN0RQprNx0jn0l6Rs2f1zKJJH9Ejq9lMR6T9TRL9VNCdQwqNuLac2LXUSyWERwP4XC7bQudeFGLbMAehpUiyUMTI8BZ2Gxii7yvpSlUFY07VhOZXtX1TdP1W8ldclWn17VIhqBZ8LpIpjpbwKtd4SA3UNtukSeliDbDgNOOJLLQ4q0Ib9MBWctXW9LJ2LCXOzbHspDP_vWhr8it_uhgP9wPDgfPyW1uypBg-OULsg5SoV-CMTiPNsyppOT0uoX5D7kxajk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwzV1fb9MwELfGkBAvG__XAcMgmHhYtthOmhSJh7KuWihMldZJewuO46wVJZmaFhQ-DF-Fr8ad82frmMTTJJ7tOI59vt9dfPc7Ql4DRErXF8zSTMcW4K1t-WDlWglDvBV2FLuYO_z5qH144nw8dU9XyK86FwYmkcNIubnEx1N9HicVwwDb-zYViDHe9yqIcqCLH-Ci5e-DHuznG877B6P9Q6uqImBJ4dlzS_iO31FcSQ3GDpjrTOmOpzpcah-xM_Fl4komQbIFS7hKwNW0lZQOT7gbMaUEjHuL3MbrQXTuuvvHtaZvg-1kEi47DmYveW7NXHR5qoh6Kl9Gvb9M2asRmZcgrr9OfjeLYyJbvu4u5tGu-nmFN_L_Xb17ZK2yrmm3PA73yYpOH5DtYUnPXezQ0UW2Wb5Dt-nwgri7eEiyY0Omu5hp6wOAe0x7JryFZgkNZkh1NQP9MdXUXHzQQXdEg4AG6XgSTbBm0Tvam-QKQ2ILfATggw4zdEkK6yAdI69JekbNH9gymSR_RE5uZDEek9U0S_UGoToGVRtx7Tmx6ygWywiOiXC43baFTryoRbZgH8NKoeShiRXgLGw2sUXe1hIVqorOHauKTK_r-qrpel5ymFzX6WUtliFoGLw2kqnOFvBqVzjIEdS2W-RJKabNMOC8I5kstHhLAtx0QPby5ZZ0MjYs5o7NsTzk5r8-9AW5M-z1w0_B0eApuctNNRKMwnxGVkEo9HOwCefRljmYlHy5aVn-A45AbLw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structure-Based+Design+of+Irreversible+Human+KAT+II+Inhibitors%3A+Discovery+of+New+Potency-Enhancing+Interactions&rft.jtitle=ACS+medicinal+chemistry+letters&rft.au=Tuttle%2C+Jamison+B.&rft.au=Anderson%2C+Marie&rft.au=Bechle%2C+Bruce+M.&rft.au=Campbell%2C+Brian+M.&rft.date=2013-01-10&rft.pub=American+Chemical+Society&rft.issn=1948-5875&rft.eissn=1948-5875&rft.volume=4&rft.issue=1&rft.spage=37&rft.epage=40&rft_id=info:doi/10.1021%2Fml300237v&rft_id=info%3Apmid%2F24900560&rft.externalDocID=PMC4027135
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1948-5875&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1948-5875&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1948-5875&client=summon